Portfolio company
Aspen Neuroscience
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
5 investors
Sectors
About
This biotechnology firm develops personalised autologous cell therapies to replace damaged neurons in patients with Parkinson's disease.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Herantis Pharma
This clinical-stage biotechnology company develops neurorestorative drug therapies for patients living with Parkinson's disease.
Axent
Axent Biosciences develops cell therapies using engineered biomaterials to treat Parkinson's disease for patients and healthcare providers.
Neuroplast
This company develops autologous stem cell therapies to treat patients with neurodegenerative diseases including spinal cord injuries and amyotrophic lateral sclerosis.
Neumirna Therapeutics
This biotechnology company develops microRNA-based therapies to treat patients with neurological disorders, including drug-resistant epilepsy and Parkinson's disease.
Savanna Biotherapeutics
This company develops induced pluripotent stem cell-derived microglia cell therapies to treat patients with neurodegenerative diseases and other central nervous system disorders.
Neurona Therapeutics
This company develops off-the-shelf regenerative neural cell therapies for patients with drug-resistant epilepsy and other chronic disorders of the central nervous system.
BE Therapeutics
This company develops engineered brain and spinal cord tissues to repair central nervous system damage for patients with neurodegeneration, stroke or trauma.
NeurOdys Therapeutics
This biotechnology company develops small molecule therapies for patients with neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.